

بسم الله الرحمن الرحيم



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
على هذه الأفلام قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of
15-25- c and relative humidity 20-40%.

بعض الوثائق الأصلية تالفة

بالرسالة صفحات لم ترد بالاصل

**Serum concentrations of growth hormone, insulin
like growth factor-I, procollagen-I and prolactin
in healthy infants and children and in children
with growth disorders**

THESIS

**Submitted for partial Fulfillment of MD degree
In pediatrics**

By

**Mohamed Abd El-Maboud Mohamed
(M.B.B.Ch., M.Sc.)
Faculty of medicine, El-Minia University**

Under supervision of

**Prof. Dr. Hassan Fathy Nageeb
Professor and Head of pediatric department,
Faculty of medicine, Cairo University
Beni-Sueef Branch**

**Prof. Dr. Salem Ahmed Sallam
Professor and Head of pediatric department,
Faculty of medicine, El-Minia University**

**Dr. Nabil Gamel Mohamed
Assistant professor of pediatrics
Faculty of medicine, El-Minia University**

**Dr. Mahmoud El-Rehany
Assistant professor of Biochemistry
Faculty of medicine, El-Minia University**

**Faculty of medicine
El-Minia University
2000**

A handwritten signature in black ink, consisting of stylized, flowing letters, likely the author's name, Mohamed Abd El-Maboud Mohamed.

**TO
MY PARENTS,
MY WIFE
&
MY SON (ZIAD)**

CONTENTS

PAGE

-INTRODUCTION AND AIM OF THE WORK.....	1
-REVIEW OF LITERATURE.....	4
-Physiology of growth.....	5
-Anthropometry.....	14
-Growth hormone.....	24
-Insulin like growth factor-I.....	43
-Procollagen-I.....	59
-Prolactin.....	71
-Growth disorders.....	80
-PATIENTS AND METHODS.....	119
-RESULTS.....	130
-DISCUSSION.....	173
-SUMMARY AND CONCLUSSION.....	192
-REFERENCES.....	197
-ARABIC SUMMARY	

LIST OF ABBREVIATIONS

ACTH	: Adrenocorticotrophic hormone
ALS	: Acid labile aubaunit
Arg-Gly-Asp	: Arginine glycine asparagine
BUN	: Blood urea nitrogen
CAMP	: Cyclic adenosine monophosphate
CBC	: Complete blood count
CDGM	: Constitutional delay of growth and maturation
CDNA	: Complementary deoxyribonucleic acid
COL1AI	: Collagen 1 AI
DNA	: Deoxyribonucleic acid
EGF	: Epidermal growth factor
EGF-TGF- α	: Epidermal growth factor-Transforming growth factor- α
ESR	: Erythrocyte sedimentation rate
ESRD	: End stage renal disease
GH	: Growth hormone
GHBP	: Growth hormone binding protein
GHRH	: Growth hormone releasing hormone
GnRH	: Gonadotropin releasing hormone
H.C.	: Head circumference
HER	: Human epidermal growth factor receptor
HGH-V	: Human growth hormone variant
HPL	: Human placental lactogen
I ¹²⁵	: Iodine 125
IDDM	: Insuli dependant diabetes mellitus
IGFBP	: Insulin like growth factor binding protein
IGF-I	: Insulin like growth factor-I
IGF-II	: Insulin like growth factor-II

IRMA	:Immunoradiometric assay
IUGR	:Intrauterine growth retardation
JAK/STAT	:Janus kinases/Signal transduction activating transcription
Kb	:Kilo bite
Kd	:Kilo dalton
LH	:Luteinizing hormone
MRNA	:Messenger ribonucleic acid
NHANES-III	National health and nutritional examination survey
NHCS	National centre for health statistics
NSB	Non specific binding
NSILA	Non suppressible insulin like activity
PACAP	Pituitary adenylate cyclase activating polypeptide
PHM-27	A peptide with structural homology to vaso active intestinal peptides
PIF	Prolactin inhibitory factor
PINP	Propeptide of type I procollagen
Pit-1	Pituitary 1 gene
PRF	Prolactin releasing factor
PRL	Prolactin
RIA	:Radioimmunoassay
SD	:Standard deviation
SM-A	:Somatomedin-A
SM-C	:Somatomedin-C
TGF- α	:Transforming growth factor- α
TRH	:Thyroid stimulating hormone
Mg/L	:Microgram/Litre

(7)	Serum levels of GH, IGF-I, PINP and prolactin in patients and controls.	144
(8)	Serum levels of GH, IGF-I, PINP and prolactin in different ages of patients.	146
(9)	Serum levels of GH, IGF-I, PINP and prolactin in male and female patients.	147
(10)	Serum levels of GH, IGF-I, PINP and prolactin in different ages of controls.	148
(11)	Serum levels of GH, IGF-I, PINP and prolactin in male and female controls.	149
(12)	Serum levels of GH, IGF-I, PINP and prolactin in different groups of patients.	150
(13)	Serum levels of GH, IGF-I, PINP and prolactin in control groups from 5 th to > 75 th percentiles according to weight and height.	152
(14)	Serum levels of GH, IGF-I, PINP and prolactin in control groups from 5 th to > 75 th percentiles according to height only.	153
(15)	Serum levels of GH, IGF-I, PINP and prolactin in control groups from 5 th to > 75 th percentiles according to weight and height and those due to height only.	154
(16)	Serum levels of GH, IGF-I, PINP and prolactin in patients with primary growth disorders.	155
(17)	Serum levels of GH, IGF-I, PINP and prolactin in patients with secondary growth disorders.	157
(18)	Serum levels of GH, IGF-I, PINP and prolactin in patients with idiopathic short stature.	158

(19)	Serum levels of GH, IGF-I, PINP and prolactin in patients with hypopituitarism and other secondary growth disorders.	159
(20)	Correlation between GH, IGF-I, PINP and prolactin in patients.	160
(21)	Correlation between GH, IGF-I, PINP and prolactin in controls.	161
(22)	Correlation between age, weight and height and GH, IGF-I, PINP and prolactin in patients.	162
(23)	Correlation between age, weight and height and GH, IGF-I, PINP and prolactin in controls	163

LIST OF FIGURES

FIGURE		PAGE
I	Technique for measuring recumbent length.	20
II	Technique for measuring erect height using the stadiometer.	20
III	Charts for boys and girls of length by age and weight by age.	21-22
IV	Charts for boys and girls of weight by length, head circumference by age.	23
V	Covalent structure of human growth hormone.	24
VI	C, X-ray crystallographic model of a single growth hormone molecule binding to the extracellular domain of two adjacent GH receptors.	29
VII	Growth hormone receptor activation of the JAK/STAT signaling pathway.	29
VIII	Schematic representation of multiple sites of growth hormone action.	33
IX	Structure of the mammalian IGF-I gene.	47
X	Biochemical evaluation of growth disorders.	118
1	Serum levels of GH in different groups of patients.	164
2	Serum levels of IGF-I in different groups of patients.	165
3	Serum levels of PINP in different groups of patients.	166
4	Serum levels of prolactin in different groups of patients.	167
5	Correlation between GH and IGF-I in patients with growth disorders.	168
6	Correlation between GH and PINP in patients with growth disorders.	168

7	Correlation between GH and IGF-I in patients with growth disorders.	169
8	Correlation between GH and prolactin in patients with growth disorders.	169
9	Correlation between IGF-I and PINP in patients with growth disorders.	170
10	Correlation between IGF-I and prolactin in patients with growth disorders.	170
11	Correlation between GH and IGF-I in controls.	171
12	Correlation between GH and PINP in controls.	171
13	Correlation between IGF-I and PINP in controls.	172

INTRODUCTION AND AIM OF THE WORK

INTRODUCTION

The most fundamental characteristic of childhood is that it is a time of growth. Children normally grow in a predictable manner. Deviation from a normal pattern of growth can be the first manifestation of a wide variety of disease processes that include both endocrine and non-endocrine disorders and can involve any organ system of the body. Growth disorders have been subdivided into primary growth abnormalities, in which the defect appears to be intrinsic to the growth plate, secondary growth disorders which are growth failure resulting from chronic disease or endocrine disorders and disorders of bone growth which includes genetic disorders.

INTRODUCTION AND AIM OF THE WORK

growth hormone (GH) secretion (CBGM) maturation but also bone turnover and mineral deposition, to alterations of GH secretion may induce disturbances in skeletal growth and mineral metabolism (Giorgio, 1991).

Insulin like growth factor-I (IGF-I) has metabolic, mitogenic and differentiating effects on a wide variety of cell types. During fasting or chronic food restriction, the concentration of circulating IGF-I is reduced and correlates with growth rate in humans, indicating an important role for IGF-I in the regulation of growth. The expression of IGF-I is considered to be controlled by several hormones but mainly by GH (Katz-Heggen et al., 1995).